131 related articles for article (PubMed ID: 8323767)
1. Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas.
Becciolini A; Porciani S; Lanini A; Tommasi M; Olmi P; Chiavacci A
Acta Oncol; 1993; 32(3):295-9. PubMed ID: 8323767
[TBL] [Abstract][Full Text] [Related]
2. Serum SCC-Ag in head and neck squamous cell carcinoma.
Palermo F; Carniato A; Fede A; Boccaletto F; Marchiori C
Int J Biol Markers; 1990; 5(3):118-20. PubMed ID: 2286775
[TBL] [Abstract][Full Text] [Related]
3. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.
Kandiloros D; Eleftheriadou A; Chalastras T; Kyriou L; Yiotakis I; Ferekidis E
Med Oncol; 2006; 23(4):463-70. PubMed ID: 17303904
[TBL] [Abstract][Full Text] [Related]
5. Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Travassos DC; Fernandes D; Massucato EMS; Navarro CM; Bufalino A
J Oral Pathol Med; 2018 Jan; 47(1):3-10. PubMed ID: 28600896
[TBL] [Abstract][Full Text] [Related]
6. Sedimentation rate and serum thymidine kinase activity: prognostic factors in squamous cell head and neck cancer.
Fontana X; Dassonville O; Néri J; Vallicioni J; Santini J; Milano G; Combon P; Lapalus F; Demard F
Head Neck; 1993; 15(5):425-32. PubMed ID: 8407315
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer.
Molina R; Torres MD; Moragas M; Perez-Villa J; Filella X; Jo J; Farrus B; Giménez N; Traserra J; Ballesta AM
Tumour Biol; 1996; 17(2):81-9. PubMed ID: 8658017
[TBL] [Abstract][Full Text] [Related]
8. [Serum tumor markers SCC, TATI and TPS: value in follow-up of females with cervix cancer].
Joura E; Gitsch G; Kainz C; Fröhlich B; Biegelmayr C; Kölbl H
Gynakol Geburtshilfliche Rundsch; 1992; 32 Suppl 1():115. PubMed ID: 1286308
[No Abstract] [Full Text] [Related]
9. Squamous cell carcinoma antigen and protein-bound sialic acid in the management of head and neck cancer.
Bhatavdekar JM; Patel DD; Vora HH; Balar DB
Int J Biol Markers; 1991; 6(4):237-40. PubMed ID: 1795131
[TBL] [Abstract][Full Text] [Related]
10. High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
Rosenberg V; Pastorekova S; Zatovicova M; Vidlickova I; Jelenska L; Slezak P
Bratisl Lek Listy; 2016; 117(4):201-4. PubMed ID: 27075382
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
[TBL] [Abstract][Full Text] [Related]
12. Use of tumor markers in the management of head and neck cancer.
Rosati G; Riccardi F; Tucci A
Int J Biol Markers; 2000; 15(2):179-83. PubMed ID: 10883893
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma.
Pardo L; Valero C; López M; García J; Camacho M; Quer M; León X
Auris Nasus Larynx; 2017 Jun; 44(3):313-318. PubMed ID: 27401121
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of squamous-cell carcinoma antigen and tissue polypeptide antigen in the follow-up of patients with vulvar cancer.
Hefler L; Frischmuth K; Heinze G; Sliutz G; Leodolter S; Reinthaller A; Kainz C; Tempfer C
Int J Cancer; 1999 Oct; 83(2):167-70. PubMed ID: 10471522
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
16. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
Sproston AR; Roberts SA; Davidson SE; Hunter RD; West CM
Br J Cancer; 1995 Dec; 72(6):1536-40. PubMed ID: 8519673
[TBL] [Abstract][Full Text] [Related]
17. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
Kuropkat C; Lippert BM; Werner JA
Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
[TBL] [Abstract][Full Text] [Related]
18. Squamous cell carcinoma antigen in serum for monitoring of head and neck and uterine cervical squamous cell carcinomas after radiotherapy.
Shirato H; Ichimura W; Wakushima H; Nishioka T; Suzuki K
Acta Oncol; 1993; 32(6):663-6. PubMed ID: 8260185
[TBL] [Abstract][Full Text] [Related]
19. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM
Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
